Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to “Buy” Rating by StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Monday.

Separately, Cantor Fitzgerald restated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Trading Up 1.7 %

Shares of Supernus Pharmaceuticals stock traded up $0.55 during trading hours on Monday, hitting $32.70. 380,535 shares of the company were exchanged, compared to its average volume of 467,460. The business has a 50-day moving average of $35.58 and a 200-day moving average of $35.06. Supernus Pharmaceuticals has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a market capitalization of $1.83 billion, a price-to-earnings ratio of 30.56 and a beta of 0.83.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now directly owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company’s stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock valued at $440,263 in the last three months. 9.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vident Advisory LLC grew its holdings in Supernus Pharmaceuticals by 2.2% in the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after purchasing an additional 309 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of Supernus Pharmaceuticals by 7.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock worth $190,000 after buying an additional 369 shares in the last quarter. Bank of Montreal Can grew its stake in Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after acquiring an additional 473 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after acquiring an additional 560 shares in the last quarter. Finally, HighTower Advisors LLC raised its position in Supernus Pharmaceuticals by 7.3% during the fourth quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company’s stock worth $330,000 after acquiring an additional 624 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.